Condition
Polycystic Ovarian Disease (PCOD)
A hormonal disorder in which the ovaries develop multiple small cysts and release eggs irregularly, leading to menstrual irregularity and elevated androgens.
Overview
Aetiology
The exact cause of polycystic ovarian disease is not fully understood, but it is generally regarded as a multifactorial condition arising from a combination of genetic predisposition, hormonal imbalance, and metabolic disturbance.
Genetic Factors
A family history of polycystic ovaries, irregular menstruation, or type 2 diabetes is common, suggesting an inherited tendency toward the hormonal and metabolic changes seen in the condition.
Hormonal Imbalance
An excess of androgens (male sex hormones) and disrupted signaling between the pituitary gland and the ovaries interfere with normal follicle development and ovulation, so immature follicles accumulate as small cysts within the ovaries.
Insulin Resistance
Reduced sensitivity to insulin leads to higher circulating insulin levels, which stimulate the ovaries to produce more androgens and contribute to weight gain, further worsening the hormonal imbalance.
Presentation
Symptoms
Polycystic ovarian disease typically presents with irregular, infrequent, or absent menstrual periods, difficulty conceiving, and signs of androgen excess such as acne, oily skin, excess facial and body hair, and scalp hair thinning. Weight gain and enlarged ovaries containing multiple small cysts are also common.
Assessment
Diagnostic Considerations
Diagnosis is based on a combination of menstrual history, clinical signs of androgen excess, blood tests measuring reproductive and androgen hormones, and pelvic ultrasound demonstrating the characteristic multiple ovarian cysts.
Assessment
Differential Diagnosis
- Polycystic ovary syndrome (PCOS)
- Hypothyroidism
- Hyperprolactinemia
- Congenital adrenal hyperplasia
- Androgen-secreting tumors
Context
Comorbidities
Polycystic ovarian disease is associated with an increased risk of infertility, type 2 diabetes, metabolic syndrome, obesity, abnormal uterine bleeding, and mood disturbances.
The Compounds
Research Compounds (3)
Individual molecules studied for polycystic ovarian disease (pcod). These are research findings, not supplements to take — each page states how far the evidence goes.
Ellagic Acid
Polyphenol (hexahydroxydiphenic acid dilactone)
A polyphenol you mostly don't absorb. In plants it's bound as ellagitannins (punicalagins etc.); free ellagic acid barely reaches the blood, and gut bacteria convert it to urolithins — the metabolites that actually circulate, and only in some people. So most "ellagic acid" evidence is really pomegranate/ellagitannin extract or the urolithin-A metabolite, not the isolate.
Liquiritin
Flavonoid (flavanone glycoside)
Liquiritin is the principal flavanone glycoside of licorice root (Glycyrrhiza) and the plant's characteristic flavonoid marker. Its best-developed preclinical story is antidepressant — it raises brain serotonin and noradrenaline in rodent despair tests — alongside antioxidant, anti-inflammatory, cardioprotective and PCOS-protective signals; all of it is animal or cell work on the isolate, with no human trials.
Resveratrol
Stilbene (stilbenoid polyphenol)
The famous "red wine" stilbene — and a textbook hype-vs-reality case. It is well absorbed but has near-zero oral bioavailability (it circulates as conjugates, not free resveratrol); human trials are small, dose- and subgroup-dependent, and often flatly null in healthy people; and its fame carries two credibility scars — the failed SRT501 drug program and a major research-fraud scandal. The studied form is trans-resveratrol, and supplements come from Japanese knotweed, not grapes.